Global X Genomics & Biotechnology UCITS ETF

An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.

GNOM trades at 12.332 USD today, its price has risen 1.79% in the past 24 hours. Track more dynamics on GNOM price chart.

GNOM net asset value is 12.85 today — it's risen 12.47% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.

GNOM assets under management is ‪140.23 M‬ USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.

GNOM price has risen by 10.35% over the last month, and its yearly performance shows a 68.35% increase. See more dynamics on GNOM price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 12.47% over the last month, showed a 23.28% increase in three-month performance and has increased by 77.82% in a year.

GNOM fund flows account for ‪76.91 M‬ USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.

GNOM invests in stocks. See more details in our Profile section.

No, GNOM isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.

In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, GNOM technical analysis shows the buy rating and its 1-week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating GNOM shows the buy signal. See more of GNOM technicals for a more comprehensive analysis.

No, GNOM doesn't pay dividends to its holders.

GNOM trades at a premium (1.80%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.

GNOM shares are issued by Mirae Asset Global Investments Co., Ltd.

GNOM follows the Solactive Genomics v2 Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

The fund started trading on Nov 2, 2021.